LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 140

Search options

  1. Article ; Online: Urgent need for evaluation of point-of-care tests as an RT-PCR-sparing strategy for the diagnosis of Covid-19 in symptomatic patients.

    Zavascki, Alexandre P

    Epidemiology and infection

    2021  Volume 149, Page(s) e35

    MeSH term(s) COVID-19 ; COVID-19 Testing ; Humans ; Point-of-Care Testing ; Reverse Transcriptase Polymerase Chain Reaction ; SARS-CoV-2
    Language English
    Publishing date 2021-01-28
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 632982-2
    ISSN 1469-4409 ; 0950-2688
    ISSN (online) 1469-4409
    ISSN 0950-2688
    DOI 10.1017/S0950268821000170
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Colistin versus colistin plus meropenem for severe infections.

    Zavascki, Alexandre P

    The Lancet. Infectious diseases

    2018  Volume 18, Issue 5, Page(s) 493–494

    MeSH term(s) Carbapenems ; Colistin ; Gram-Negative Bacteria ; Meropenem
    Chemical Substances Carbapenems ; Meropenem (FV9J3JU8B1) ; Colistin (Z67X93HJG1)
    Language English
    Publishing date 2018-05-31
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 2061641-7
    ISSN 1474-4457 ; 1473-3099
    ISSN (online) 1474-4457
    ISSN 1473-3099
    DOI 10.1016/S1473-3099(18)30212-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Which trial do we need? One or two antimicrobials with anti-pseudomonal activity for the empirical treatment of Ventilator-associated pneumonia due to Gram-negative bacteria.

    Yusuf, Erlangga / Zavascki, Alexandre P / Endeman, Henrik / Kalil, Andre C

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

    2023  

    Language English
    Publishing date 2023-08-11
    Publishing country England
    Document type Journal Article
    ZDB-ID 1328418-6
    ISSN 1469-0691 ; 1470-9465 ; 1198-743X
    ISSN (online) 1469-0691
    ISSN 1470-9465 ; 1198-743X
    DOI 10.1016/j.cmi.2023.08.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Clinical Characteristics of Covid-19 in China.

    Zavascki, Alexandre P / Falci, Diego R

    The New England journal of medicine

    2020  Volume 382, Issue 19, Page(s) 1859

    MeSH term(s) Betacoronavirus ; COVID-19 ; China ; Coronavirus ; Coronavirus Infections ; Humans ; Pandemics ; Pneumonia, Viral ; SARS-CoV-2
    Keywords covid19
    Language English
    Publishing date 2020-03-27
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc2005203
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Can ceftolozane-tazobactam treat nosocomial pneumonia?

    Kalil, Andre C / Zavascki, Alexandre P

    The Lancet. Infectious diseases

    2019  Volume 19, Issue 12, Page(s) 1266–1267

    MeSH term(s) Cephalosporins ; Cross Infection ; Double-Blind Method ; Humans ; Meropenem ; Pneumonia ; Tazobactam
    Chemical Substances Cephalosporins ; ceftolozane (37A4IES95Q) ; Meropenem (FV9J3JU8B1) ; Tazobactam (SE10G96M8W)
    Language English
    Publishing date 2019-09-25
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 2061641-7
    ISSN 1474-4457 ; 1473-3099
    ISSN (online) 1474-4457
    ISSN 1473-3099
    DOI 10.1016/S1473-3099(19)30523-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Brazil's Family Health Strategy.

    Zavascki, Alexandre P

    The New England journal of medicine

    2015  Volume 373, Issue 13, Page(s) 1277–1278

    MeSH term(s) Community Health Services/organization & administration ; Family Health ; Female ; Humans ; Male ; National Health Programs/organization & administration ; Primary Health Care/organization & administration ; Universal Coverage
    Language English
    Publishing date 2015-09-24
    Publishing country United States
    Document type Comment ; Letter
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc1509056#SA2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Colistin versus polymyxin B for the treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections.

    Vieceli, Tarsila / Henrique, Lilian Rodrigues / Rech, Tatiana Helena / Zavascki, Alexandre Prehn

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

    2024  

    Abstract: ... PMB groups, respectively, P = 0.54 (incidence rate, 18.9 and 21.7/1000 patients-day in CMS and PMB ... groups, respectively, P = 0.62). No statistically significant difference in 30-day mortality rate was ... differences between groups (47.8 % and 57.4 % for CMS and PMB, respectively, P = 0.83). In-hospital mortality ...

    Abstract Background: To assess the effectiveness of colistin (administered as colistimethate sodium-CMS) and polymyxin B (PMB) for the treatment of bloodstream infections (BSIs) caused by carbapenem-resistant Klebsiella pneumoniae (CRKP).
    Materials and methods: This retrospective cohort included hospitalized adult patients with CRKP BSIs from a single tertiary-care hospital. A univariate analysis comparing CMS and PMB groups was carried out and an inverse-probability propensity score (IPPS) was created. An IPPS-adjusted Cox regression model for 30-day mortality was performed including covariates potentially associated with mortality.
    Results: A total of 100 patients with CRKP BSI (87 were KPC-producing isolates) were included. The 30-day mortality was 42.0 %:17/46 (38.8 %) and 25/54 (44.6 %) patients of CMS and PMB groups, respectively, P = 0.54 (incidence rate, 18.9 and 21.7/1000 patients-day in CMS and PMB groups, respectively, P = 0.62). No statistically significant difference in 30-day mortality rate was observed in a model adjusted for Pitt bacteremia score, high-risk primary site and IPPS, which included age, intensive care unit admission, minimal inhibitory concentration, previous colonization by CRKP, diabetes mellitus, malignancy, neutropenia, meropenem use before BSI, adjuvant therapy with meropenem and amikacin, and time to start polymyxin. Acute kidney injury (AKI) occurred in 52.0 % of patients, with no significant differences between groups (47.8 % and 57.4 % for CMS and PMB, respectively, P = 0.83). In-hospital mortality was 47,7 % and 50.0 % in CMS and PMB groups, respectively, P = 0.82.
    Conclusion: There was no difference in 30-day mortality and AKI rates among patients with CRKP BSI treated with PMB or CMS.
    Language English
    Publishing date 2024-01-18
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 1355399-9
    ISSN 1437-7780 ; 1341-321X
    ISSN (online) 1437-7780
    ISSN 1341-321X
    DOI 10.1016/j.jiac.2024.01.012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Substantial Diversity in Cocirculating Omicron Lineages in Hospital Setting, Porto Alegre, Brazil.

    Andreis, Tiago F / Cantarelli, Vlademir V / da Silva, Marcelo B / Helfer, Mateus S / Brust, Flávia R / Zavascki, Alexandre P

    Emerging infectious diseases

    2023  Volume 29, Issue 12, Page(s) 2583–2586

    Abstract: We describe substantial variant diversity among 23 detected SARS-CoV-2 Omicron lineage viruses cocirculating among healthcare workers and inpatients (272 sequenced samples) from Porto Alegre, Brazil, during November 2022-January 2023. BQ.1 and related ... ...

    Abstract We describe substantial variant diversity among 23 detected SARS-CoV-2 Omicron lineage viruses cocirculating among healthcare workers and inpatients (272 sequenced samples) from Porto Alegre, Brazil, during November 2022-January 2023. BQ.1 and related lineages (61.4%) were most common, followed by BE.9 (19.1%), first described in November 2022 in the Amazon region.
    MeSH term(s) Humans ; Brazil/epidemiology ; Health Personnel ; Hospitals ; Inpatients ; SARS-CoV-2
    Language English
    Publishing date 2023-11-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1380686-5
    ISSN 1080-6059 ; 1080-6040
    ISSN (online) 1080-6059
    ISSN 1080-6040
    DOI 10.3201/eid2912.230880
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Polymyxins for the treatment of extensively-drug-resistant Gram-negative bacteria: from pharmacokinetics to bedside.

    Zavascki, Alexandre P

    Expert review of anti-infective therapy

    2014  Volume 12, Issue 5, Page(s) 531–533

    Abstract: The initial use of polymyxins, polymyxin B and colistin (administered as a pro-drug colistin methanesulfonate sodium [CMS]), mostly relied on old pharmacokinetic (PK) studies that lacked appropriate methodology. In recent years, many PK studies in both ... ...

    Abstract The initial use of polymyxins, polymyxin B and colistin (administered as a pro-drug colistin methanesulfonate sodium [CMS]), mostly relied on old pharmacokinetic (PK) studies that lacked appropriate methodology. In recent years, many PK studies in both animals and humans have provided more consistent evidence supporting better use of these invaluable antibiotics. However, translating preclinical data to clinical practice is not always an easy task and some may experience difficulties on how recent knowledge on polymyxins can be applied into the patients' care. Although many questions are still unresolved, there are consistent data able to improve clinical practice when prescribing initial and maintenance doses of both polymyxin B and CMS. Considering the importance of optimal use of polymyxins, this editorial discusses recent PK findings and how to take advantage of them at the bedside to improve the treatment of patient with extensively-drug-resistant Gram-negative bacterial infections.
    MeSH term(s) Anti-Bacterial Agents/pharmacokinetics ; Anti-Bacterial Agents/pharmacology ; Area Under Curve ; Colistin/analogs & derivatives ; Colistin/metabolism ; Colistin/pharmacokinetics ; Colistin/pharmacology ; Drug Administration Schedule ; Drug Dosage Calculations ; Drug Resistance, Multiple, Bacterial ; Gram-Negative Bacteria/drug effects ; Gram-Negative Bacteria/growth & development ; Gram-Negative Bacterial Infections/drug therapy ; Gram-Negative Bacterial Infections/microbiology ; Humans ; Microbial Sensitivity Tests ; Polymyxin B/pharmacokinetics ; Polymyxin B/pharmacology
    Chemical Substances Anti-Bacterial Agents ; Polymyxin B (1404-26-8) ; colistinmethanesulfonic acid (DL2R53P963) ; Colistin (Z67X93HJG1)
    Language English
    Publishing date 2014-05
    Publishing country England
    Document type Editorial
    ZDB-ID 2181279-2
    ISSN 1744-8336 ; 1478-7210
    ISSN (online) 1744-8336
    ISSN 1478-7210
    DOI 10.1586/14787210.2014.902307
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top